The FDA has approved a new drug for the treatment of rosacea.

The oral drug, branded Emrosi, was approved to treat inflammatory lesions associated with the disease, which mostly affects women and men in the age group of 30 to 60 years.

Emrosi will be commercially available late in the first quarter or early in the second quarter of 2025, according to Journey, the drug's manufacturer.

The drug, also known as DFD-29, is a low-dose minocycline, an antibiotic used for skin infections.

Journey had sought approval of DFD-29 for the treatment of both inflammation and redness or erythema associated with rosacea.

The FDA's decision was based on two late-stage clinical trials where the drug met the main goal after 16 weeks of treatment with no significant safety issues, showing a reduction in the total inflammatory lesion count and facial redness in both studies when tested against Oracea and placebo.